François Rozet

14PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersCancer diagnosisBiological physics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Feb 14, 2025
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.

Nadine Houédé, Thierry Chevallier, François Audenet

|May 30, 2024
A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma.

Pierre-Etienne Gabriel, Géraldine Cancel-Tassin, François Audenet

|Feb 19, 2024
Scoring system for prediction of overall survival in patients with renal cell carcinoma T3aN0M0.

Caio Vinícius Suartz, Maurício Dener Cordeiro, Paulo Afonso de Carvalho

|Jan 02, 2023
Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.

Yanish Soorojebally, Yann Neuzillet, Mathieu Roumiguié

|Dec 03, 2022
A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.

Yann Neuzillet, Priscilla Leon, Thomas Seisen

Pageof 3

Frequent Collaborators

3 joint publications

Gwenaelle Gravis

3 joint publications

Constance Thibault

2 joint publications

Yohann Loriot

2 joint publications

Mathieu Roumiguié